CXCL12 and ovarian cancer: Indeed, TCDD, the highly toxic AhR agonist, cannot be used in the clinic to specifically target AhR, despite its positive effect against breast cancer, by disrupting the CXCR4/CXCL12 pathway [64], or ovarian cancer cells [65].